Author

Chandler Bray

Imperial College London

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

Adrián BenitoiD· 1 shared Alexandros SiskosiD· 1 shared Anke M. NijhuisiD· 1 shared Chiharu WickremesingheiD· 1 shared Cristina Domingo BalcellsiD· 1 shared Edward W. TateiD· 1 shared Flora McKinneyiD· 1 shared Hector C. KeuniD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adrián BenitoORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

RAS/PI3K pathway mutations sensitise epithelial ovarian cancer cells to a PARP/NAMPT inhibitor combination

Michael Gruet, Yitao Xu, Lijie An, Yurui Ma, Cristina Domingo Balcells, Katie Tyson, Laila C. Evangelista, Sarah Spear, Yuewei Xu, Flora McKinney, Julia Babuta, Chandler Bray, Chiharu Wickremesinghe, Alexandros Siskos, Anke M. Nijhuis, , Hector C. Keun

This study identifies RAS/PI3K pathway mutations as a biomarker for sensitivity to PARP/NAMPT inhibitor combination therapy in epithelial ovarian cancer.

Communications Biology · Dec 19, 2025Peer-reviewedCancer Biology